三星医疗（601567）公告，公司拟将存放于股份回购专用证券账户中已回购尚未使用的575.54万股股份 用于注销。本次注销完成后，公司总股本预计将由14.11亿股变更为14.05亿股。公司已向上海证券交易 所提交注销回购股份575.54万股的申请，注销日为2025年7月31日。本次变更回购股份用途并注销事项 符合相关法律法规要求，有利于优化股东投资回报，增强投资者信心。 ...

三星医疗(601567.SH)公告称，公司下属控股墨西哥子公司Nansen Instrumentos de Precision de Mexico中 标美国NexGrid智能电表框架项目，合同金额总计2,955.50万美元，约合2.12亿人民币。合同履行将对公 司经营工作和经营业绩产生积极影响，但对公司业务、经营的独立性不产生影响。 ...

Summary of Key Points Core Viewpoint - Ningbo SANSING Medical Electric Co., Ltd. has announced the provision of a guarantee for its subsidiary, Foxytech Sp.zo.o, to support its business needs through a bank guarantee totaling approximately USD 147.18 million, equivalent to about RMB 10.56 million, with a guarantee period until August 22, 2030 [2][4]. Group 1: Guarantee Overview - The company applied for a bank guarantee from HSBC Bank (China) Co., Ltd. Ningbo Branch, with a total amount of approximately USD 147.18 million [2]. - The guarantee is intended to support Foxytech, a subsidiary under the company's control, which allows the company to effectively manage and mitigate guarantee risks [2][4]. - The board of directors approved the guarantee during meetings held on April 24, 2025, and May 16, 2025, with a total guarantee limit of RMB 974.85 million for various financing needs [2][5]. Group 2: Financial Details - As of the announcement date, the total amount of guarantees provided by the company to its subsidiaries is RMB 974.85 million, which represents 80.69% of the company's net assets attributable to shareholders for the year 2024 [6]. - The actual guarantee balance for the subsidiaries is RMB 561.91 million, accounting for 46.51% of the company's net assets for the same period [6]. - The company has no overdue guarantees, indicating a stable financial position regarding its guarantee obligations [6]. Group 3: Board's Opinion - The board believes that providing guarantees to its subsidiaries is necessary for their operational needs and that the associated risks are manageable [5]. - The guarantee complies with relevant laws and regulations, ensuring that it does not harm the interests of the company or minority shareholders [5].

Group 1 - As of July 29, 2025, Samsung Medical's stock price closed at 21.70 yuan, down 1.68% from the previous trading day [1] - The trading volume on that day was 357 million yuan, with a turnover rate of 1.17% [1] - Samsung Medical's main business involves the research, development, production, and sales of smart power distribution products, including smart meters and terminal devices [1] Group 2 - On the evening of July 29, Samsung Medical announced that the company has no overdue guarantees [2]

金融界消息 截至2025年7月29日收盘，三星医疗（601567）报收于21.7元，下跌1.68%，换手率1.17%， 成交量16.48万手，成交金额3.57亿元。 资金流向方面，今日主力资金净流出1552.42万元，占比成交额4.35%。其中，超大单净流出1502.73万 元、占成交额4.21%，大单净流出49.70万元、占成交额0.14%，中单净流出流入2076.26万元、占成交额 5.81%，小单净流出523.84万元、占成交额1.47%。 三星医疗最新一期业绩显示，截至2025一季报，公司营业总收入36.31亿元、同比增长20.03%，归属净 利润4.89亿元，同比增长34.33%，扣非净利润4.60亿元，同比增长22.62%，流动比率1.804、速动比率 1.277、资产负债率47.79%。 天眼查商业履历信息显示，宁波三星医疗电气股份有限公司，成立于2007年，位于宁波市，是一家以从 事仪器仪表制造业为主的企业。企业注册资本141100.6571万人民币，实缴资本40050万人民币。公司法 定代表人为沈国英。 通过天眼查大数据分析，宁波三星医疗电气股份有限公司共对外投资了19家企业，参与招投标项目 ...

证券日报网讯7月29日晚间，三星医疗（601567）发布公告称，公司无逾期担保的情况。 ...

7月29日，三星医疗今日收盘21.7元，下跌1.68%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到12.84倍，总市值306.19亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)4三星医疗12.8413.552.43306.19亿行业平均 36.9341.253.7395.33亿行业中值39.4242.722.8349.12亿1炬华科技11.3012.371.9982.22亿2新联电子 12.5118.331.4348.88亿3正泰电器12.7613.031.17505.01亿5金杯电工13.0613.111.8174.57亿6海兴电力 14.2313.201.82132.26亿7友讯达15.5413.882.6227.50亿8柘中股份17.0685.002.1762.17亿9长高电新 17.9418.211.8745.90亿10明阳电气18.2818.902.61125.19亿11宏力达18.3717.091.0038.07亿12四方股份 18.5920.162.99144.24亿 来源：金融界 截至2025年一季报，共有39家机构持仓三星医疗，其中基金39家，合计持股数61 ...

证券代码：601567 证券简称：三星医疗 公告编号：临2025-059 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | Foxytech 147.18 | Sp.zo.o（以下简称"福克斯"） 万美元（约 万人民币） 1055.73 | | --- | --- | --- | --- | | 担保对象 | 实际为其提供的担保余额 | 2,140.15 | 万元（含本次担保） | | | 是否在前期预计额度内 | 是 | □否 □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 □不适用：_________ | 二、被担保人基本情况 | 被担保人类型 | 法人 | | --- | --- | | | □其他______________（请注明） | | 被担保人名称 | Foxytech Sp.zo.o | | 被担保人类型及上市公 | □全资子公司 | ...

Group 1: Industry Overview - The private hospital sector has seen a significant rise, with an increase of over 20% this year, driven by favorable policies and pandemic control measures [1] - The rapid growth of private hospitals, at a rate of 2,000 per year, raises questions about the sustainability of this business model as key players adjust their strategies [1] - The market is experiencing a divide, with some companies thriving while others, like Hengkang Medical, face bankruptcy and restructuring [1] Group 2: Company Performance - The private hospital, United Family Healthcare, reported a second-quarter revenue of 549 million yuan, a 28% increase from the first quarter, but faced a loss of 160 million yuan in the first quarter [2][3] - United Family Healthcare's investment expenditures rose from 112 million yuan in 2016 to 535 million yuan in 2018, focusing on high-end positioning and expansion [3] - The company is shifting its focus from obstetrics to a more comprehensive medical service model, with obstetrics revenue now accounting for only 23% of total income [3][4] Group 3: Market Dynamics - The influx of pharmaceutical companies into the hospital sector was driven by supportive policies, but subsequent regulatory changes have severely impacted profitability [5][6] - The number of private hospitals surpassed public hospitals, reaching 14,518, but faced a downturn due to stringent regulations and profit compression [6] - The financial struggles of Hengkang Medical, which reported losses of 1.388 billion yuan in 2018 and 2.498 billion yuan in 2019, exemplify the challenges faced by over-leveraged private hospitals [6] Group 4: Future Outlook - The future of private hospitals may depend more on technological advancements rather than capital investment, as public hospitals receive substantial government support [8] - Recent acquisitions of struggling private hospitals by state-owned enterprises indicate a potential shift in ownership dynamics within the sector [8] - The need for long-term investment strategies in the hospital sector is emphasized, as short-term profit motives can harm development [9]

Core Viewpoint - Samsung Medical (601567) has shown a positive stock performance with a closing price of 22.18 yuan, reflecting a 3.16% increase from the previous week, indicating strong market interest and potential growth opportunities [1] Company Announcements - Samsung Medical's subsidiary, Brazil Nansen, has won a procurement framework contract for transformers with CPFL Energia SA in Brazil, amounting to 3.41 billion yuan, which is expected to positively impact the company's operational performance and is projected to account for 2.33% of the audited revenue for 2024 [1] - The company has provided guarantees for its subsidiaries, including a guarantee of 100,000 USD (approximately 716,200 yuan) for Ningbo Aux Intelligent Technology Co., Ltd. and a guarantee of 69,000 USD (approximately 496,200 yuan) for Brazil Nansen, with total external guarantees amounting to 974.85 million yuan, representing 80.69% of the latest audited net assets [2]